M2AS34 Stock Overview
Develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Masimo Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$21.00 |
52 Week High | US$25.24 |
52 Week Low | US$15.46 |
Beta | 0.97 |
11 Month Change | -1.69% |
3 Month Change | -5.23% |
1 Year Change | 34.62% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -46.01% |
Recent News & Updates
Recent updates
Shareholder Returns
M2AS34 | BR Medical Equipment | BR Market | |
---|---|---|---|
7D | 0% | -1.6% | -0.4% |
1Y | 34.6% | 16.0% | -2.2% |
Return vs Industry: M2AS34 exceeded the BR Medical Equipment industry which returned 16% over the past year.
Return vs Market: M2AS34 exceeded the BR Market which returned -2.2% over the past year.
Price Volatility
M2AS34 volatility | |
---|---|
M2AS34 Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.1% |
Market Average Movement | 4.4% |
10% most volatile stocks in BR Market | 8.5% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: M2AS34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine M2AS34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 3,800 | Michelle Brennan | www.masimo.com |
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions.
Masimo Corporation Fundamentals Summary
M2AS34 fundamental statistics | |
---|---|
Market cap | R$49.50b |
Earnings (TTM) | R$451.83m |
Revenue (TTM) | R$11.74b |
109.6x
P/E Ratio4.2x
P/S RatioIs M2AS34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
M2AS34 income statement (TTM) | |
---|---|
Revenue | US$2.04b |
Cost of Revenue | US$1.02b |
Gross Profit | US$1.02b |
Other Expenses | US$943.80m |
Earnings | US$78.60m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.47 |
Gross Margin | 50.05% |
Net Profit Margin | 3.85% |
Debt/Equity Ratio | 52.8% |
How did M2AS34 perform over the long term?
See historical performance and comparison